ENTRY       D09575                      Drug
NAME        Ibalizumab (USAN/INN);
            Ibalizumab-uiyk;
            Trogarzo (TN)
  ABBR      IBA
PRODUCT     TROGARZO (Theratechnologies)
SEQUENCE    (Heavy chain)
            QVQLQQSGPE VVKPGASVKM SCKASGYTFT SYVIHWVRQK PGQGLDWIGY INPYNDGTDY
            DEKFKGKATL TSDTSTSTAY MELSSLRSED TAVYYCAREK DNYATGAWFA YWGQGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
            EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
            (Light chain)
            DIVMTQSPDS LAVSLGERVT MNCKSSQSLL YSTNQKNYLA WYQQKPGQSP KLLIYWASTR
            ESGVPDRFSG SGSGTDFTLT ISSVQAEDVA VYYCQQYYSY RTFGGGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
  TYPE      Peptide
REMARK      ATC code: J05AX23
            Product: D09575<US>
EFFICACY    Antiviral, HIV fusion inhibitor, Anti-CD4 antibody
  DISEASE   HIV-1 infection [DS:H01563]
  TYPE      Monoclonal antibody
COMMENT     Treatment of HIV/AIDS in HIV-1 infected patients
TARGET      CD4 [HSA:920] [KO:K06454]
  PATHWAY   hsa03250(920)  Viral life cycle - HIV-1
            hsa04060(920)  Cytokine-cytokine receptor interaction
            hsa04514(920)  Cell adhesion molecules
            hsa04660(920)  T cell receptor signaling pathway
            hsa05170(920)  Human immunodeficiency virus 1 infection
STR_MAP     map07053  Anti-HIV agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AX Other antivirals
                 J05AX23 Ibalizumab
                  D09575  Ibalizumab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Agents, Other
               Ibalizumab
                D09575  Ibalizumab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD4
                 D09575  Ibalizumab (USAN/INN) &lt;US&gt;
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               CD4 antibody
                D09575  Ibalizumab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09575
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09575
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09575
DBLINKS     CAS: 680188-33-4
            PubChem: 124490315
///
